Rheumatoid Arthritis

4 years 5 months ago
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh


4 years 5 months ago
When prescribing hydroxychloroquine for RA, SLE, or other rheumatic diseases, do you routinely order an EKG (either before or during)? #ACR20 @RheumNow

4 years 5 months ago
Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased trigs and BMI associated NAFLD @rheumnow #ACR20 Abstr#0181 https://t.co/WLPuf6Ga1D


4 years 5 months ago
Using #MachineLearning, multimorbidity patterns predominant for #rheumatoid arthritis: cardiometabolic, cardiopulmonary & #Mentalhealth/pain disorders. Patterns similar to non-RA pts but prevalence higher in RA pts. @RheumNow #ACR20 abstr#0179 https://t.co/zfCxzKquDV


4 years 5 months ago
Even in early RA, there’s pain – and then there’s pain. Non-articular pain common very common in early RA (even at 12m) and a/w worse outcomes.
Early RA isn't just about the inflammation: understand/treat the cause(s) of pain!
from CATCH @earlyarthritis #ACR20 ABST0187 @RheumNow https://t.co/kR4waqHUnm

Abatacept in RA and ILD Patients: Dr Richard Conway
Dr. Richard Conway discusses abstract #0233 presented Friday at the 2020 ACR virtual annual meeting.
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
Dr. Vibeke Strand discusses opening day at ACR 2020, sessions she's looking forward, and provides a sneak peek into The Great Debate.

4 years 5 months ago
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis https://t.co/3PrWlIGnB8 #RA #HCO #NASH - HCO decreases fatty liver

4 years 5 months ago
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity

4 years 5 months ago
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs